0001193125-12-340595.txt : 20120807
0001193125-12-340595.hdr.sgml : 20120807
20120807145654
ACCESSION NUMBER: 0001193125-12-340595
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120630
FILED AS OF DATE: 20120807
DATE AS OF CHANGE: 20120807
EFFECTIVENESS DATE: 20120807
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: BB BIOTECH AG
CENTRAL INDEX KEY: 0000924223
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-06964
FILM NUMBER: 121012923
BUSINESS ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
BUSINESS PHONE: 411724 59 59
MAIL ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
13F-HR
1
d390193d13fhr.txt
FORM 13F HOLDINGS REPORT
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
Form 13F COVER PAGE
Report for Calendar Year or Quarter Ended: June 30, 2012
Check here if Amendment [ ]; Amendment Number:
This Amendment (Check only one.): [ ] is a restatement.
[ ] adds new holdings
entries.
Institutional Investment Manager Filing this Report:
Name: BB Biotech AG
Address: Vordergasse 3
Schaffhausen Switzerland CH-8200
Form 13F File Number: 28-6964
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Pascal Schmucki
Title: SIGNING AUTHORITY
Phone: 41 (44) 267 67 00
Signature, Place, and Date of Signing: /s/ Pascal Schmucki
-----------------------------------------
Schaffhausen, Switzerland, August 3, 2012
Report Type (Check only one.):
[X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting
manager are reported in this report.)
[ ] 13F NOTICE. (Check here if no holdings reported are in this report, and
all holdings are reported by other reporting manager(s).)
[ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for
this reporting manager are reported in this report and a portion are
reported by other reporting manager(s).)
================================================================================
Form 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 3
Form 13F Information Table Entry Total: 20
Form 13F Information Table Value Total: $ 1,073,529
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.
No. Form 13F File Number Name
1 28-11193 Biotech Focus N.V.
2 28-11191 Biotech Invest N.V.
3 28-11189 Biotech Target N.V.
BB BIOTECH AG
FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
--------------- -------- --------- --------- ----------------- -------- ----------- -------- ------------------------
TITLE OF VALUE SHS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE
--------------- -------- --------- --------- --------- ------ -------- ----------- -------- ---------- ------ -----
Achillion COM 00448Q201 9,792 1,579,340 SH DEFINED 3 1,579,340 NONE NONE
Pharmaceuticals
Inc
Alexion COM 015351109 44,685 450,000 SH DEFINED 2 450,000 NONE NONE
Pharmaceuticals
Inc
Amylin COM 032346108 61,290 2,173,391 SH DEFINED 2 2,173,391 NONE NONE
Pharmaceuticals
Inc
Ariad COM 04033A100 53,408 3,103,331 SH DEFINED 3 3,103,331 NONE NONE
Pharmaceuticals
Inc
Biomarin COM 09061G101 38,612 975,545 SH DEFINED 2 975,545 NONE NONE
Pharmaceutical
Inc
Celgene Corp COM 151020104 174,708 2,723,000 SH DEFINED 2 2,723,000 NONE NONE
Dendreon Corp COM 24823Q107 11,281 1,524,500 SH DEFINED 2 1,524,500 NONE NONE
Endocyte Inc COM 29269A102 11,060 1,345,493 SH DEFINED 3 1,345,493 NONE NONE
Gilead COM 375558103 108,201 2,110,000 SH DEFINED 1 2,110,000 NONE NONE
Sciences Inc
Halozyme COM 40637H109 45,226 5,104,500 SH DEFINED 3 5,104,500 NONE NONE
Therapeutics
Inc
Human Genome COM 444903108 26,260 2,000,000 SH DEFINED 2 2,000,000 NONE NONE
Sciences Inc
Idenix COM 45166R204 12,850 1,250,000 SH DEFINED 3 1,250,000 NONE NONE
Pharmaceuticals
Inc
Immunogen Inc COM 45253H101 61,374 3,666,300 SH DEFINED 3 3,666,300 NONE NONE
Incyte Corp COM 45337C102 94,716 4,172,504 SH DEFINED 3 4,172,504 NONE NONE
Isis COM 464330109 88,426 7,368,800 SH DEFINED 3 7,368,800 NONE NONE
Pharmaceuticals
Inc
Onyx COM 683399109 23,689 356,500 SH DEFINED 2 356,500 NONE NONE
Pharmaceuticals
Inc
Optimer COM 68401H104 22,830 1,476,700 SH DEFINED 3 1,476,700 NONE NONE
Pharmaceuticals
Inc
The Medicines COM 584688105 36,209 1,578,417 SH DEFINED 2 1,578,417 NONE NONE
Company
Theravance Inc COM 88338T104 18,737 843,244 SH DEFINED 3 843,244 NONE NONE
Vertex COM 92532F100 130,176 2,327,900 SH DEFINED 3 2,327,900 NONE NONE
Pharmaceuticals
Inc